Transcranial Magnetic Stimulation (TMS) is a non-invasive brain stimulation technique that uses rapidly changing magnetic fields to induce electric fields in targeted regions of the brain. These electric fields generate currents in neuronal tissue, influencing neuronal activity and helping to normalize dysfunctional brain circuits in a variety of psychiatric and neurological disorders.
Unlike medication, which affects the entire brain and body, TMS is targeted and localized, focusing on specific cortical areas such as the dorsolateral prefrontal cortex (DLPFC), the dorsomedial prefrontal cortex (DMPFC), the Orbitofrontal Cortex (OFC), the supplementray or primary motor cortex (SMA, M1), or the Precuneus. This precision allows clinicians to modulate specific neural circuits while minimizing systemic side effects.
TMS treatment works through a straightforward process:
- A TMS coil is positioned on the patient’s scalp.
- Rapidly changing magnetic fields pass painlessly through the intact skull.
- Electric fields are induced in the underlying brain tissue.
- These electric fields generate currents in neuronal elements.
- Repeated stimulation promotes neuroplastic changes that can lead to lasting therapeutic effects.
TMS hardware typically consists of a stimulation device positioned on a trolley or workstation, to which different TMS coils can be connected depending on the intended application. The coil placed on the patient’s head enables painless transcranial brain stimulation with few to no side effects.
When magnetic pulses are delivered repeatedly in specific patterns, the technique is referred to as repetitive TMS (rTMS). rTMS protocols commonly use frequencies such as 10 Hz to increase cortical excitability or 1 Hz to reduce it, producing effects that extend beyond the stimulation period itself. These longer-lasting changes are thought to reflect underlying neuroplastic mechanisms and have been associated with meaningful clinical improvements across psychiatry, neurology, and neurorehabilitation.
Current evidence suggests that rTMS may exert its therapeutic effects by engaging synaptic plasticity mechanisms such as long-term potentiation (LTP) and long-term depression (LTD), while also modulating functional connectivity within distributed brain networks.
Over the past decades, TMS has proven to be an effective treatment option for a growing range of neuropsychiatric conditions, including major depressive disorder, obsessive-compulsive disorder (OCD), and neuropathic pain. Several TMS protocols have received regulatory approval, including FDA and MDR approval, and international expert guidelines have assigned Level A recommendations (definitely effective) to specific indications. Reimbursement by health insurers continues to expand worldwide.
TMS is generally well tolerated and associated with few to no side effects. Most patients experience minimal discomfort, if any, while benefiting from sustained clinical improvements.
Importantly, delivering TMS safely, effectively, and responsibly requires appropriate education, training, and adherence to international standards. This is where our team of internationally recognized TMS experts plays a vital role, providing accredited TMS Training and Certification Programmes designed to equip clinicians and technicians with the knowledge and competencies required for high-quality clinical practice.”
